Molecular detection of Helicobacter pylori antibiotic resistance in stool vs biopsy samples

Table 1 Demographics of endoscopy and urea breath test patients

	Endoscopy	UBT	Pvalue	95%CI
Total	n = 389	n = 227
Mean age (SD)	52.3 (16.4)	39.6 (12.6)	< 0.001	10.22-15.18
Male	42.2% (n = 164)	30.4% (n = 69)	< 0.005	3.68-19.60
Primary H. pylori infection	14.7% (n = 57)	33.0% (n = 75)	< 0.001	11.07-25.65
Mean age (SD)	48.4 (14.9)	41.4 (13.0)	< 0.005	2.19-11.81
Male	52.6% (n = 30)	33.3% (n = 25)	0.03	1.23-36.29

Table 2 Molecular detection of Helicobacter pylori infection and resistance-mediating mutations using biopsies from CLO-positive endoscopy patients and stool samples of Urea Breath Test-positive patients

	Biopsy Specimens	Stool specimens	P value	95%CI
Total analysed	n = 55	n = 66
H. pylori DNA positive	98.2% (n = 54/55)	80.3 % (n = 53/66)	< 0.005	6.10-29.66
Clarithromycin resistant	51.9% (n = 28/54)	96.2 % (n = 51/53)	< 0.001	27.70-58.71
Fluoroquinolone resistant	9.3 % (n = 5/54)1	13 % (n = 6/46)1	0.55	-9.99-18.28

¹Fluoroquinolone and clarithromycin mutations present. H. pylori: Helicobacter pylori.

Table 3 Concordance in the detection of Helicobacter pylori and antibiotic resistance-mediating mutations between results obtained using biopsies vs stool samples from individual Campylobacter-like organisms-positive endoscopy patients

	Biopsy Specimens	Stool specimens	Concordance
Total analysed	n = 20	n = 20
H. pylori DNA positive	95% (n =19/20)	90% (n = 18/20)	85% (n = 17/20)
Clarithromycin resistant1	52.9% (n = 9/17)	100.0% (n = 17/17)	52.9% (n = 9/17)
Fluoroquinolone resistant1	23.5% (n = 4/17)	52.9% (n = 9/17)	35.3% (n = 6/17)

¹Only samples where H. pylori DNA was detected were analysed. H. pylori: Helicobacter pylori.